Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
:CHRS
CHRS Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CHRS Stock 12 Month Forecast
Average Price Target
$7.00
▲(733.33% Upside)
| Highest Price Target$7.00 | Average Price Target$7.00 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Barclays
Reiterated
03/24/25
H.C. Wainwright
Reiterated
03/11/25
Truist Financial
Reiterated
03/11/25
TD Cowen
Reiterated
03/11/25
Robert W. Baird
$4→$6
Buy
614.29%
Upside
Reiterated
12/05/24
Coherus Biosciences price target raised to $6 from $4 at BairdCoherus Biosciences price target raised to $6 from $4 at Baird
Citi
$8
Buy
852.38%
Upside
Assigned
12/04/24
Citi Out Positive on Coherus Biosciences (CHRS): Erasing the $230M convert debt due in 2026 extinguishes a much-debated overhangCiti analyst Yigal Nochomovitz reiterated a Buy rating and $8.00 price target on Coherus Biosciences (NASDAQ: CHRS).
JonesTrading
―
Buy
―
Reiterated
10/07/24
TD Cowen reiterates Buy Rating on Coherus Biosciences (CHRS)TD Cowen analyst Michael Nedelcovych, Ph.D. reiterated a Buy rating on Coherus Biosciences (NASDAQ: CHRS).
UBS
$1.5
Hold
78.57%
Upside
Downgraded
08/15/24
Coherus Biosciences: Hold Rating with Downward Revenue Projections and Price Target Revision
Maxim Group
―
Hold
―
Reiterated
05/17/24
Coherus Biosciences (CHRS) Gets a Hold from Maxim Group
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Barclays
Reiterated
03/24/25
H.C. Wainwright
Reiterated
03/11/25
Truist Financial
Reiterated
03/11/25
TD Cowen
Reiterated
03/11/25
Robert W. Baird
$4→$6
Buy
614.29%
Upside
Reiterated
12/05/24
Coherus Biosciences price target raised to $6 from $4 at BairdCoherus Biosciences price target raised to $6 from $4 at Baird
Citi
$8
Buy
852.38%
Upside
Assigned
12/04/24
Citi Out Positive on Coherus Biosciences (CHRS): Erasing the $230M convert debt due in 2026 extinguishes a much-debated overhangCiti analyst Yigal Nochomovitz reiterated a Buy rating and $8.00 price target on Coherus Biosciences (NASDAQ: CHRS).
JonesTrading
―
Buy
―
Reiterated
10/07/24
TD Cowen reiterates Buy Rating on Coherus Biosciences (CHRS)TD Cowen analyst Michael Nedelcovych, Ph.D. reiterated a Buy rating on Coherus Biosciences (NASDAQ: CHRS).
UBS
$1.5
Hold
78.57%
Upside
Downgraded
08/15/24
Coherus Biosciences: Hold Rating with Downward Revenue Projections and Price Target Revision
Maxim Group
―
Hold
―
Reiterated
05/17/24
Coherus Biosciences (CHRS) Gets a Hold from Maxim Group
CHRS Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Mar 25
Strong Buy
5
4
6
8
7
Buy
5
6
7
4
4
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
10
13
12
11
Each month's total comprises the sum of three months' worth of ratings.
CHRS Financial Forecast
CHRS Stock Forecast FAQ
What is CHRS’s average 12-month price target, according to analysts?
Based on analyst ratings, Coherus Biosciences’s 12-month average price target is $7.00.
What is CHRS’s upside potential, based on the analysts’ average price target?
Coherus Biosciences has 733.33% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CHRS a Buy, Sell or Hold?
Coherus Biosciences has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Coherus Biosciences’s price target?
The average price target for Coherus Biosciences is $7.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 733.33% Increase from the current price of $0.84.
The highest analyst price target is $7.00 ,the lowest forecast is $7.00. The average price target represents 733.33% Increase from the current price of $0.84.
What do analysts say about Coherus Biosciences?
Coherus Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of CHRS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.